Correlation Between Orphazyme and ChemoMetec

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Orphazyme and ChemoMetec at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Orphazyme and ChemoMetec into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Orphazyme AS and ChemoMetec AS, you can compare the effects of market volatilities on Orphazyme and ChemoMetec and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Orphazyme with a short position of ChemoMetec. Check out your portfolio center. Please also check ongoing floating volatility patterns of Orphazyme and ChemoMetec.

Diversification Opportunities for Orphazyme and ChemoMetec

0.21
  Correlation Coefficient

Modest diversification

The 3 months correlation between Orphazyme and ChemoMetec is 0.21. Overlapping area represents the amount of risk that can be diversified away by holding Orphazyme AS and ChemoMetec AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ChemoMetec AS and Orphazyme is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Orphazyme AS are associated (or correlated) with ChemoMetec. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ChemoMetec AS has no effect on the direction of Orphazyme i.e., Orphazyme and ChemoMetec go up and down completely randomly.

Pair Corralation between Orphazyme and ChemoMetec

Assuming the 90 days trading horizon Orphazyme AS is expected to generate 0.46 times more return on investment than ChemoMetec. However, Orphazyme AS is 2.16 times less risky than ChemoMetec. It trades about -0.22 of its potential returns per unit of risk. ChemoMetec AS is currently generating about -0.16 per unit of risk. If you would invest  130,000  in Orphazyme AS on January 17, 2024 and sell it today you would lose (25,020) from holding Orphazyme AS or give up 19.25% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Orphazyme AS  vs.  ChemoMetec AS

 Performance 
       Timeline  
Orphazyme AS 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Orphazyme AS has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in May 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
ChemoMetec AS 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days ChemoMetec AS has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's primary indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders.

Orphazyme and ChemoMetec Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Orphazyme and ChemoMetec

The main advantage of trading using opposite Orphazyme and ChemoMetec positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Orphazyme position performs unexpectedly, ChemoMetec can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ChemoMetec will offset losses from the drop in ChemoMetec's long position.
The idea behind Orphazyme AS and ChemoMetec AS pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Other Complementary Tools

Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Transaction History
View history of all your transactions and understand their impact on performance
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals